Compositions and methods
Inventors
McKenzie, Gregory • McKenzie, Mary-Jane Lombardo • Cook, David N. • Vulic, Marin • von Maltzahn, Geoffrey • Goodman, Brian • Aunins, John Grant • Henn, Matthew R. • Berry, David Arthur • Winkler, Jonathan
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
Core Innovation
The invention provides a capsule composition for treating or reducing the severity of at least one symptom of a gastrointestinal disease, disorder, or condition associated with dysbiosis. The composition comprises a purified population of Acetivibrio ethanolgignens spores in an amount effective to populate the gastrointestinal tract of a subject. It is derived from ethanol- or heat-treated fecal material, is substantially depleted of residual habitat product, and contains spores not detectable in the fecal material before treatment.
The composition serves to restore gut microbiota in target dysbiosis conditions, including Clostridioides difficile infection or recurrent infection. Associated animal and clinical studies report protection in Clostridioides difficile mouse models, increased microbiome diversity and Bacteroides abundance, and reductions in selected opportunistic pathogens. The disclosure also outlines mouse evaluations for reducing fecal carbapenem-resistant Klebsiella pneumoniae and catalogs bacterial operational taxonomic units identifying Acetivibrio ethanolgignens as a spore-forming bacterium.
Claims Coverage
The provided relevant claims identify one independent claim comprising four inventive features.
Treatment of dysbiosis-associated gastrointestinal conditions
The composition is for treating or reducing a severity of at least one symptom of a gastrointestinal disease, disorder, or condition associated with a dysbiosis in a subject.
Purified Acetivibrio ethanolgignens spores in a capsule
The composition comprises a capsule and a purified population of Acetivibrio ethanolgignens spores in an amount effective to populate a gastrointestinal tract in the subject.
Derivation from treated fecal material and depletion of residual habitat product
The composition is derived from fecal material subjected to ethanol treatment or heat treatment and is substantially depleted of a residual habitat product of the fecal material.
Pre-treatment non-detection
Acetivibrio ethanolgignens is not detectable in the fecal material before the ethanol treatment or the heat treatment.
The independent claim combines a dysbiosis-associated gastrointestinal treatment composition with a capsule containing purified Acetivibrio ethanolgignens spores, and specifies the composition's derivation from treated fecal material, depletion of residual habitat product, and pre-treatment non-detection condition.
Stated Advantages
Treating or reducing the severity of at least one symptom of a gastrointestinal disease, disorder, or condition associated with dysbiosis.
Restoring gut microbiota.
Reported protection against Clostridioides difficile in animal models.
Reported increases in microbiome diversity and Bacteroides abundance following treatment.
Reported reductions in selected opportunistic pathogens.
Absence of recurrence reported in a group of eight patients with recurrent infection.
No treatment-related serious adverse events reported in the eight-patient group.
Documented Applications
Treating or reducing the severity of at least one symptom of a gastrointestinal disease, disorder, or condition associated with dysbiosis in a subject, including Clostridioides difficile-induced diarrhea, irritable bowel syndrome, pathogen or pathobiont infection or colonization, colitis, metabolic disorder, and Crohn's disease.
Administration to patients with recurrent infection.
Evaluating oral bacterial compositions for reducing fecal carbapenem-resistant Klebsiella pneumoniae in a mouse study.
Evaluating the protective effects of ethanol- and heat-treated preparations in animal models.
Use in a capsule composition, including a delayed-release capsule.
Interested in licensing this patent?